Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05856448 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus
A Phase 2 study of Systemic Lupus Erythematosus, sponsored by Galapagos.
- Active
- Registry status
- Phase 2
- Development phase
- 186
- Enrollment target
- 20
- Study locations
NCT05856448: Active Phase 2 study of Systemic Lupus Erythematosus, sponsored by Galapagos.
NCT05856448 is a Phase 2 study of Systemic Lupus Erythematosus that is active but no longer recruiting, run by Galapagos. The registered enrollment target is 186 participants, below the 378-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (51% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05856448, a Phase 2 study of Systemic Lupus Erythematosus, is active but no longer recruiting, sponsored by Galapagos.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 186 participants
- Enrollment target
- 20
- Study locations
Study Summary
A study evaluating the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GLPG3667 administered orally once daily for 48 weeks in approximately 180 adult participants with active Systemic Lupus Erythematosus (SLE).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG GLPG3667
Study Locations (20)
Florida
- Arthritis & Rheumatic Disease Specialties - Aventura
- Omega Research DeBary - DeBary
- Alloy Clinical Research, LLC - Kissimmee
- San Marcus Research Clinic - Miami
- Advanced Pharma - Miami - Miami
- Professional Research Center - Miami
- Integral Rheumatology & Immunology Specialists - Plantation
- Alliance Clinical Research of Tampa - Tampa
California
- University of California San Diego - La Jolla
- Desert Medical Advances - Rancho Mirage
- Millennium Clinical Trials - Simi Valley
- Inland Rheumatology Clinical Trials - Upland
- Upland Rheumatology Center - Upland
Tennessee
- New Phase Research & Development - Knoxville
- Office of Ramesh C. Gupta MD / Shelby Research LLC - Tennessee - Memphis
Arizona
- University of Arizona College of Medicine - Tucson - Tucson
New Mexico
- Albuquerque Clinical Trials - Albuquerque
North Carolina
- DJL Clinical Research - Charlotte
Oklahoma
- Lynn Institute of Tulsa - Tulsa
Texas
- Care and Cure Clinic - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2023-06-28 |
| Est. Completion | 2026-03 |
| Phase | Phase 2 |
What the registry record for NCT05856448 still lists
NCT05856448 is an interventional study that assigns participants to a tested intervention. The registered 186 participants enrollment target is mid-sized for trials with a published cap, below the 378-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (51% lower).
The record links to 1 condition, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05856448 names 20 study sites across 8 states, led by Florida, California, Tennessee.
Frequently Asked Questions
What is clinical trial NCT05856448 about?
NCT05856448 is a clinical study titled "A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus". A study evaluating the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GLPG3667 administered orally once daily for 48 weeks in approximately 180 adult participants with active Systemic Lupus Erythematosus (SLE).
What is the current status of trial NCT05856448?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 186 participants. The study started on 2023-06-28. Estimated completion is 2026-03.
What conditions does trial NCT05856448 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus.
What interventions are being tested in trial NCT05856448?
The interventions under investigation include: Placebo (DRUG), GLPG3667 (DRUG).
Who is sponsoring clinical trial NCT05856448?
This trial is sponsored by Galapagos, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05856448 being conducted?
This trial has 20 study locations across Arizona, California, Florida, New Mexico, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05856448's enrollment target sits among peer trials
186 44th of 99 higher than 56 of 99 other Systemic Lupus Erythematosus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Systemic Lupus Erythematosus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus
RECRUITING · Phase 2
-
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
RECRUITING · Phase 2
-
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
RECRUITING · Phase 2
-
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
RECRUITING · Phase 2
-
Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases
RECRUITING · Phase 2
-
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03567889 · 186 participants · Phase 3
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
- NCT05281471 · 186 participants · Phase 3
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- NCT05405595 · 186 participants · Phase 1
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
- NCT05762107 · 186 participants · Phase 2
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI